Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
Related Questions
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
When do you start cyclophosphamide for the treatment of anti-NMDA receptor encephalitis?
How would you manage a patient with LGI-1 encephalitis with faciobracial dystonic seizures who has not improved with 3 days of intravenous steroids?
What is your disease modifying treatment of choice for a patient with relapsing remitting multiple sclerosis with treated, well controlled HIV?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
What are the possible or expected MRI findings or changes in progressive MS?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
